Comparative Pharmacology
Head-to-head clinical analysis: EPICORT versus LOCORTEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPICORT versus LOCORTEN.
EPICORT vs LOCORTEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epicort is a corticosteroid that exerts anti-inflammatory and immunosuppressive effects by binding to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit prostaglandin and leukotriene synthesis, reduce cytokine release, and suppress immune cell activation.
IV: 50 mg every 8 hours over 30 minutes.
For mild to moderate dermatoses: Apply a thin film to affected area twice daily. For severe dermatoses: Apply a thin film to affected area three to four times daily. Topical use only. Not for ophthalmic use.
None Documented
None Documented
Terminal half-life is 1.5–2 hours in adults; prolonged to 3–4 hours in severe hepatic impairment
100 hours (terminal). Clinical context: prolonged in hepatic impairment; single daily dosing sufficient for psoriasis.
Renal (70% as unchanged drug and inactive metabolites), biliary/fecal (30%)
Renal: ~75% (inactive metabolites); biliary/fecal: ~25%. <1% unchanged.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid